{
    "info": {
        "Nasdaq_Traded": "Y",
        "Symbol": "ATOS",
        "Security_Name": "Atossa Therapeutics, Inc. - Common Stock",
        "Listing_Exchange": "Q",
        "Market_Category": "S",
        "ETF": "N",
        "Round_Lot_Size": "100.0",
        "Test_Issue": "N",
        "Financial_Status": "N",
        "CQS_Symbol": "",
        "NASDAQ_Symbol": "ATOS",
        "NextShares": "N"
    },
    "history": [],
    "recommendationTrend": {
        "trend": [
            {
                "period": "0m",
                "strongBuy": 0,
                "buy": 1,
                "hold": 0,
                "sell": 0,
                "strongSell": 0
            },
            {
                "period": "-1m",
                "strongBuy": 0,
                "buy": 2,
                "hold": 0,
                "sell": 0,
                "strongSell": 0
            },
            {
                "period": "-2m",
                "strongBuy": 0,
                "buy": 2,
                "hold": 0,
                "sell": 0,
                "strongSell": 0
            },
            {
                "period": "-3m",
                "strongBuy": 0,
                "buy": 1,
                "hold": 0,
                "sell": 0,
                "strongSell": 0
            }
        ],
        "maxAge": 86400
    },
    "summaryDetail": {
        "maxAge": 1,
        "priceHint": 4,
        "previousClose": 0.708,
        "open": 0.7199,
        "dayLow": 0.68,
        "dayHigh": 0.7299,
        "regularMarketPreviousClose": 0.708,
        "regularMarketOpen": 0.7199,
        "regularMarketDayLow": 0.68,
        "regularMarketDayHigh": 0.7299,
        "payoutRatio": 0,
        "beta": 1.653647,
        "forwardPE": -3.424286,
        "volume": 635967,
        "regularMarketVolume": 635967,
        "averageVolume": 513509,
        "averageVolume10days": 656210,
        "averageDailyVolume10Day": 656210,
        "bid": 0.71,
        "ask": 0.722,
        "bidSize": 1100,
        "askSize": 900,
        "marketCap": 91055320,
        "fiftyTwoWeekLow": 0.5,
        "fiftyTwoWeekHigh": 1.62,
        "fiftyDayAverage": 0.7354,
        "twoHundredDayAverage": 0.93875,
        "currency": "USD",
        "fromCurrency": null,
        "lastMarket": null,
        "algorithm": null,
        "tradeable": false
    },
    "earnings": {
        "maxAge": 86400,
        "earningsChart": {
            "quarterly": [
                {
                    "date": "3Q2021",
                    "actual": -0.04,
                    "estimate": -0.04
                },
                {
                    "date": "4Q2021",
                    "actual": -0.04,
                    "estimate": -0.04
                },
                {
                    "date": "1Q2022",
                    "actual": -0.04,
                    "estimate": -0.05
                },
                {
                    "date": "2Q2022",
                    "actual": -0.05,
                    "estimate": -0.06
                }
            ],
            "currentQuarterEstimate": -0.06,
            "currentQuarterEstimateDate": "3Q",
            "currentQuarterEstimateYear": 2022,
            "earningsDate": [
                1677456000,
                1677801600
            ]
        },
        "financialsChart": {
            "yearly": [
                {
                    "date": 2018,
                    "revenue": 0,
                    "earnings": -11404934
                },
                {
                    "date": 2019,
                    "revenue": 0,
                    "earnings": -17239777
                },
                {
                    "date": 2020,
                    "revenue": 0,
                    "earnings": -17828000
                },
                {
                    "date": 2021,
                    "revenue": 0,
                    "earnings": -20606000
                }
            ],
            "quarterly": [
                {
                    "date": "3Q2021",
                    "revenue": 0,
                    "earnings": -5197145
                },
                {
                    "date": "4Q2021",
                    "revenue": 0,
                    "earnings": -4831538
                },
                {
                    "date": "1Q2022",
                    "revenue": 0,
                    "earnings": -4786000
                },
                {
                    "date": "2Q2022",
                    "revenue": 0,
                    "earnings": -6672000
                }
            ]
        },
        "financialCurrency": "USD"
    },
    "calendarEvents": {
        "maxAge": 1,
        "earnings": {
            "earningsDate": [
                1677456000,
                1677801600
            ],
            "earningsAverage": -0.06,
            "earningsLow": -0.06,
            "earningsHigh": -0.06
        },
        "dividendDate": "2018-04-20T00:00:00.000Z"
    },
    "upgradeDowngradeHistory": {
        "history": [
            {
                "epochGradeDate": "2020-09-17T00:00:00.000Z",
                "firm": "Ascendiant Capital",
                "toGrade": "Buy",
                "fromGrade": "",
                "action": "init"
            },
            {
                "epochGradeDate": "2019-12-18T00:00:00.000Z",
                "firm": "Maxim Group",
                "toGrade": "Buy",
                "fromGrade": "Hold",
                "action": "up"
            },
            {
                "epochGradeDate": "2018-01-26T00:00:00.000Z",
                "firm": "Maxim Group",
                "toGrade": "Buy",
                "fromGrade": "",
                "action": "init"
            },
            {
                "epochGradeDate": "2013-10-07T00:00:00.000Z",
                "firm": "Sidoti & Co.",
                "toGrade": "Neutral",
                "fromGrade": "Buy",
                "action": "down"
            },
            {
                "epochGradeDate": "2013-04-15T00:00:00.000Z",
                "firm": "Sidoti & Co.",
                "toGrade": "Buy",
                "fromGrade": "",
                "action": "init"
            },
            {
                "epochGradeDate": "2013-03-20T00:00:00.000Z",
                "firm": "Dawson James",
                "toGrade": "Buy",
                "fromGrade": "Market Outperform",
                "action": "down"
            }
        ],
        "maxAge": 86400
    },
    "price": {
        "maxAge": 1,
        "preMarketSource": "FREE_REALTIME",
        "postMarketChangePercent": 0.0012516064,
        "postMarketChange": 0.00090003014,
        "postMarketTime": "2023-01-07T00:57:00.000Z",
        "postMarketPrice": 0.72,
        "postMarketSource": "DELAYED",
        "regularMarketChangePercent": 0.015677957,
        "regularMarketChange": 0.011099994,
        "regularMarketTime": "2023-01-06T21:00:04.000Z",
        "priceHint": 4,
        "regularMarketPrice": 0.7191,
        "regularMarketDayHigh": 0.7299,
        "regularMarketDayLow": 0.68,
        "regularMarketVolume": 635967,
        "averageDailyVolume10Day": 656210,
        "averageDailyVolume3Month": 513509,
        "regularMarketPreviousClose": 0.708,
        "regularMarketSource": "FREE_REALTIME",
        "regularMarketOpen": 0.7199,
        "exchange": "NCM",
        "exchangeName": "NasdaqCM",
        "exchangeDataDelayedBy": 0,
        "marketState": "CLOSED",
        "quoteType": "EQUITY",
        "symbol": "ATOS",
        "underlyingSymbol": null,
        "shortName": "Atossa Therapeutics, Inc.",
        "longName": "Atossa Therapeutics, Inc.",
        "currency": "USD",
        "quoteSourceName": "Delayed Quote",
        "currencySymbol": "$",
        "fromCurrency": null,
        "lastMarket": null,
        "marketCap": 91055320
    },
    "defaultKeyStatistics": {
        "maxAge": 1,
        "priceHint": 4,
        "enterpriseValue": 2935351,
        "forwardPE": -3.2686365,
        "profitMargins": 0,
        "floatShares": 118832929,
        "sharesOutstanding": 126624000,
        "sharesShort": 10597933,
        "sharesShortPriorMonth": 11426024,
        "sharesShortPreviousMonthDate": 1663200000,
        "dateShortInterest": 1665705600,
        "sharesPercentSharesOut": 0.0837,
        "heldPercentInsiders": 0.00041,
        "heldPercentInstitutions": 0.25026,
        "shortRatio": 26.5,
        "shortPercentOfFloat": 0.0837,
        "beta": 1.653647,
        "category": null,
        "bookValue": 0.558,
        "priceToBook": 1.2887096,
        "fundFamily": null,
        "legalType": null,
        "lastFiscalYearEnd": "2021-12-31T00:00:00.000Z",
        "nextFiscalYearEnd": "2023-12-31T00:00:00.000Z",
        "mostRecentQuarter": "2022-06-30T00:00:00.000Z",
        "netIncomeToCommon": -21486000,
        "trailingEps": -1.975,
        "forwardEps": -0.21,
        "lastSplitFactor": "1:12",
        "lastSplitDate": "2018-04-20T00:00:00.000Z",
        "enterpriseToEbitda": -0.138
    },
    "summaryProfile": {
        "address1": "107 Spring Street",
        "city": "Seattle",
        "state": "WA",
        "zip": "98104",
        "country": "United States",
        "phone": "206 588 0256",
        "fax": "206 902 9658",
        "website": "https://www.atossatherapeutics.com",
        "industry": "Biotechnology",
        "sector": "Healthcare",
        "longBusinessSummary": "Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.",
        "fullTimeEmployees": 6,
        "companyOfficers": [],
        "maxAge": 86400
    },
    "financialData": {
        "maxAge": 86400,
        "currentPrice": 0.7191,
        "targetHighPrice": 7,
        "targetLowPrice": 4,
        "targetMeanPrice": 5.5,
        "targetMedianPrice": 5.5,
        "recommendationMean": 2,
        "recommendationKey": "buy",
        "numberOfAnalystOpinions": 2,
        "totalCash": 125537000,
        "totalCashPerShare": 0.991,
        "ebitda": -21323000,
        "totalDebt": 0,
        "quickRatio": 33.343,
        "currentRatio": 35.185,
        "returnOnAssets": -0.09527001,
        "returnOnEquity": -0.15664,
        "freeCashflow": -8839801,
        "operatingCashflow": -17554000,
        "grossMargins": 0,
        "ebitdaMargins": 0,
        "operatingMargins": 0,
        "profitMargins": 0,
        "financialCurrency": "USD"
    }
}